Introduction
AML
Mutations in the Nucleophosmin-1 (All-In three studies performed by the British Medical Research Council (MRC), one in younger patients receiving intensive first-line treatment (MRC AML12, n = 1097)In 2011, the AMLSG initiated the randomized AMLSG 15–10 trial in older patients with newly diagnosed AML with 